IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision medicine oncology company based in South San Francisco, California. The company specializes in discovering and developing targeted therapeutics for cancer patients identified through molecular diagnostics. IDEAYA employs the concept of synthetic lethality, which focuses on exploiting genetic vulnerabilities in cancer cells to create treatments that selectively kill these cells while preserving normal cells. The company's pipeline includes several clinical-stage compounds, such as Darovasertib (IDE196), a PKC inhibitor for tumors with GNAQ or GNA11 mutations; IDE397, a MAT2A inhibitor for tumors with MTAP gene deletion; and IDE161, a PARG inhibitor for tumors with homologous recombination deficiency. IDEAYA collaborates with major pharmaceutical companies like Pfizer, Amgen, and GlaxoSmithKline to enhance its research and development efforts in precision medicine. The leadership team, led by President and CEO Yujiro S. Hata, includes experts in cancer biology and drug discovery.